Overview The production of genetically-modified mouse models and antibody reagents has revolutionized biomedical research (1-4). These research tools have made it possible to answer many questions that cannot be addressed otherwise, and have helped to define the roles of specific gene products in complex processes such as adipogenesis and obesity, diabetes mellitus, and plasma lipid metabolism. The principal objectives of the Mouse Model and Antibody Core of this Program Project Grant (PPG) are to generate gene-targeted mice and to prepare both monoclonal and polyclonal antibodies for the three projects. Genetically modified mouse models and polyclonal or monoclonal antibodies will be used in all three projects. It is both expensive and time consuming to generate new lines of mice and to create antibodies, and both require considerable technical expertise. Even though mouse and antibody reagents are critical for many modern biomedical research projects, it is very difficult for the majority of laboratories to keep the requisite techniques "up in the air" at all times. Often, the required technical expertise disappears when a technician leaves for another institution or a postdoctoral fellow departs for a faculty position. It is then inefficient, expensive, and painful to re-establish the techniques within the laboratory. Therefore, it makes sense, particularly for a PPG, to centralize these functions within a core facility. In this PPG, we are fortunate to inherit the technical expertise of BayGenomics personnel (Drs. Fong, Young, Reue, Hu) in creating genetargeted mice, and the substantial experience of Drs. Bensadoun, Fong, and Young in the production of monoclonal and polyclonal antibodies.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL090553-05
Application #
8378634
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
2013-12-14
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
5
Fiscal Year
2012
Total Cost
$461,251
Indirect Cost
$139,920
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Arnold, Arthur P; Reue, Karen; Eghbali, Mansoureh et al. (2016) The importance of having two X chromosomes. Philos Trans R Soc Lond B Biol Sci 371:20150113
Tian, Xiao Yu; Ganeshan, Kirthana; Hong, Cynthia et al. (2016) Thermoneutral Housing Accelerates Metabolic Inflammation to Potentiate Atherosclerosis but Not Insulin Resistance. Cell Metab 23:165-78
Wang, Bo; Rong, Xin; Duerr, Mark A et al. (2016) Intestinal Phospholipid Remodeling Is Required for Dietary-Lipid Uptake and Survival on a High-Fat Diet. Cell Metab 23:492-504
Allan, Christopher M; Procaccia, Shiri; Tran, Deanna et al. (2016) Palmoplantar Keratoderma in Slurp2-Deficient Mice. J Invest Dermatol 136:436-43
Dijk, Wieneke; Beigneux, Anne P; Larsson, Mikael et al. (2016) Angiopoietin-like 4 promotes intracellular degradation of lipoprotein lipase in adipocytes. J Lipid Res 57:1670-83
Ribas, Vicent; Drew, Brian G; Zhou, Zhenqi et al. (2016) Skeletal muscle action of estrogen receptor α is critical for the maintenance of mitochondrial function and metabolic homeostasis in females. Sci Transl Med 8:334ra54
Mysling, Simon; Kristensen, Kristian Kølby; Larsson, Mikael et al. (2016) The angiopoietin-like protein ANGPTL4 catalyzes unfolding of the hydrolase domain in lipoprotein lipase and the endothelial membrane protein GPIHBP1 counteracts this unfolding. Elife 5:
Mysling, Simon; Kristensen, Kristian Kølby; Larsson, Mikael et al. (2016) The acidic domain of the endothelial membrane protein GPIHBP1 stabilizes lipoprotein lipase activity by preventing unfolding of its catalytic domain. Elife 5:e12095
Vergnes, Laurent; Chin, Robert G; de Aguiar Vallim, Thomas et al. (2016) SREBP-2-deficient and hypomorphic mice reveal roles for SREBP-2 in embryonic development and SREBP-1c expression. J Lipid Res 57:410-21
Allan, Christopher M; Larsson, Mikael; Hu, Xuchen et al. (2016) An LPL-specific monoclonal antibody, 88B8, that abolishes the binding of LPL to GPIHBP1. J Lipid Res 57:1889-1898

Showing the most recent 10 out of 103 publications